BioSpace News Archive

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286).

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced its Bladder EpiCheck® test has been included in the 2022 European Association of Urology (EAU) Clinical Guidelines for non-muscle invasive bladder cancer (NMIBC).

Visus Therapeutics Inc. today announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs.

GE Healthcare and AliveCor announced a partnership to deliver medical-grade six-lead electrocardiograms taken by patients on an AliveCor KardiaMobile 6L ECG device outside of the hospital setting – at home or on the go – directly into GE Healthcare’s MUSE Cardiac Management System for physicians to view and evaluate.

Helix BioPharma Corp. today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors, Prof. Dr. S Slawomir Majewski.

Novamind Inc. is pleased to announce it has been selected by Mind Medicine, Inc. to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults.

Moderna, Inc. today announced an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of Moderna’s COVID-19 booster vaccine or an updated booster vaccine candidate, if authorized, for anticipated delivery in the second half of 2022.

Axcella Therapeutics today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the “Shares”) at a purchase price of $1.91 per share.

MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies.

Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close.